Hua Medicine (the 'Company', HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

Progression-free survival for 6 months (PFS6) in recurrent/progressive high-grade meningioma improved more than threefold ...

Tryptamine Therapeutics (Tryp) has announced the completion of subject dosing in a Phase Ib clinical trial of TRP-8803, for ...

On Tuesday, Amgen Inc (NASDAQ:AMGN) stock fell during the premarket session after the company released long-anticipated data ...

Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide ...

According to phase 2 study, MariTide achieved significant weight loss in individuals with obesity or overweight, with up to ...

Clinical-stage biotech Tryptamine Therapeutics (ASX:TYP) has successfully and safely completed obese-subject dosing in its ...

In a significant development, the pharmaceutical major Dr Reddys Laboratories has got the go-ahead from the Subject Expert ...

Technologies announced the completion of enrollment in its Phase 2 Study of PL8177, a potent melanocortin-1 receptor agonist, in ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Reaches Alignment with FDA Regarding Phase 3 Trial Plan On November 25, 2024, Imunon, Inc. (NASDAQ:IMNN) announced it had reached alignment with ...

Acadia is on track to achieve over $1 billion in annualized sales in 2025. The next phase of growth could come from two ...